Therapy Area topics
Cardiovascular
Admedus moves from one unlikely area to another
A product sale nets the Australian company some much-needed cash, but its plan for the future is highly questionable.
TCT 2019 – Abbott's aortic valve disappoints
Portico hits noninferiority, but safety looks doubtful. Abbott might want to prioritise a different approach.
Central Nervous System
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Diabetes
Upcoming events – Adamas and Ascendis look for new paths forward
Adamas hopes to make Inroads with Gocovri in MS, while Ascendis will report data for Transcon PTH in hypoparathyroidism.
Digital Health
Livongo enters the medtech float hall of fame
The deal is 2019’s second-biggest medtech flotation, and the fourth-biggest ever.
Fewer than 200 medtech VC rounds closed in 2018
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.
Oncology
A change of the guard for the world’s biggest cancer companies
Roche is set to lose its crown as the largest oncology player to the newly merged Bristol-Myers Squelgene, while Astrazeneca is forecast to streak up the rankings.
Triple meeting – clinical data, and competition, loom for Mirati
Mirati pulls a rabbit out of its hat, but the conference will serve up three new competitors too.
Respiratory
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Nuvaira hopes to go with the flow in COPD
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Various
Uncovering biopharma’s hidden treasures
Which deals accidentally brought in the biggest biopharma blockbusters? A new analysis by Vantage reveals all.
Deal-depressed third quarter leaves nowhere to hide
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.